InnovAge (INNV) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
16 Jan, 2026Executive summary
Revenue for fiscal Q1 2025 grew 12.4% year-over-year to $205.1 million, with Adjusted EBITDA rising to $6.5 million, a 500% increase, and net loss narrowing to $5.7 million from $11 million.
Participant census reached approximately 7,210, up 10% year-over-year, maintaining the largest PACE provider status in the U.S.
Employee engagement and participant Net Promoter Scores hit new highs, reflecting strong satisfaction.
Leadership transition included the appointment of Michael Scarbrough as President and COO.
Served 20 centers in six states as of September 30, 2024.
Financial highlights
Total revenues were $205.1 million, up 12.4% year-over-year, driven by higher member months and capitation rates.
Center-level contribution margin increased to $34.5 million (16.8% of revenue), up from $27.9 million (15.3%).
Net loss narrowed to $5.7 million from $11 million; Adjusted EBITDA margin improved to 3.2% from 0.7%.
Ended quarter with $39 million in cash and $46.7 million in short-term investments; total debt was $81.3 million.
Operating loss improved to $4.9 million from $10.7 million year-over-year.
Outlook and guidance
Fiscal 2025 guidance: revenue of $815–$865 million, Adjusted EBITDA of $24–$31 million, and ending census of 7,300–7,750.
De novo center losses for fiscal 2025 expected to be $18–$20 million.
Growth expected to be linear with some seasonal slowdown in Q3.
Ongoing efforts to reduce eligibility processing delays and manage labor market challenges, especially in California.
Focus on expanding PACE centers, improving payer capabilities, and maintaining high participant satisfaction and compliance.
Latest events from InnovAge
- Q2 revenue and margins surged, raising full-year guidance despite ongoing cost and regulatory risks.INNV
Q2 20263 Feb 2026 - Care coordination, trust, and tailored technology are key to advancing aging-in-place models.INNV
7th Annual Healthcare Symposium3 Feb 2026 - Revenue up 11% with margin gains and positive Adjusted EBITDA; 2025 outlook remains strong.INNV
Q4 202421 Jan 2026 - Integrated care platform drives growth, margin expansion, and superior outcomes for complex seniors.INNV
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Revenue up 10.6% to $209M; FY2025 guidance reaffirmed amid margin and regulatory pressures.INNV
Q2 20259 Jan 2026 - Scale, technology, and insourcing drive growth and margin expansion in a supportive policy environment.INNV
KeyBanc Annual Health Care Forum 202526 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.INNV
Proxy Filing1 Dec 2025 - Director elections and auditor ratification headline a meeting focused on governance and oversight.INNV
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.INNV
Proxy Filing1 Dec 2025